

K001895

**Auto Suture\* Premium Plus CEEA\* Disposable Stapler**

**DEC - 8 2000**

**IX. 510(k) Summary of Safety and Effectiveness**

**SUBMITTER:** United States Surgical  
150 Glover Avenue  
Norwalk, CT 06856

**CONTACT PERSON:** Christopher A. Graham

**DATE PREPARED:** November 27, 2000

**CLASSIFICATION NAME:** Staple, Implantable

**COMMON NAME:** Staple, Implantable

**PROPRIETARY NAME:** Auto Suture\* Premium Plus CEEA\* Disposable Stapler

**DEVICE DESCRIPTION:** The Auto Suture\* Premium Plus CEEA\* Disposable Stapler is a disposable, single patient use device which places a double staggered row of titanium staples. Immediately after staple formation, the instrument's knife blade resects the excess tissue, creating a circular anastomosis.

**INTENDED USE:** The Auto Suture Premium Plus CEEA Disposable Stapler has applications throughout the alimentary tract for the creation of end-to-end, end-to-side and side-to-side anastomoses in both open and laparoscopic surgeries.

**MATERIALS:** All component materials of the Auto Suture\* Premium Plus CEEA\* Disposable Stapler are comprised of materials which are in accordance with ISO Standard #10993-1.

**PERFORMANCE DATA:** In vitro and in vivo testing was performed to verify that the Auto Suture\* Premium Plus CEEA\* Disposable Stapler can be used during laparoscopic procedures.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

DEC - 8 2000

Mr. Christopher Graham  
Program Manager, Regulatory Affairs  
United States Surgical  
150 Glover Avenue  
Norwalk, Connecticut 06856

Re: K001895  
Trade Name: Auto Suture Premium Plus  
CEEAA Disposable Stapler  
Regulatory Class: II  
Product Code: GDW  
Dated: September 28, 2000  
Received: September 29, 2000

Dear Mr. Graham:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2 - Mr. Christopher Graham

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink, appearing to read "Celia M. Witten", is written over the typed name.

Celia M. Witten, Ph.D., M.D.  
Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

K001895

**Auto Suture\* Premium Plus CEFA\* Disposable Stapler**

**IV. Indications For Use:**

510(k) Number (if known): \_\_\_\_\_

Name: Auto Suture\* Premium Plus CEFA\* Disposable Stapler

Indications For Use:

The Auto Suture Premium Plus CEFA Disposable Stapler has applications throughout the alimentary tract for the creation of end-to-end, end-to-side and side-to-side anastomoses in both open and laparoscopic surgeries.

(Please do not write below this line - continue on another page if needed)

\_\_\_\_\_  
Concurrence of CDRII, Office of Evaluation (ODE)

Prescription Use:   X   OR Over-The-Counter Use: \_\_\_\_\_  
(Per 21 CFR §801.109)

*for Mark N. Milliken*

(Division Sign-Off)

Division of General Restorative Devices

510(k) Number \_\_\_\_\_

K001895